ArticlePharmacogenomics and personalized medicine2013
Molecular targeted therapies in metastatic melanoma.
Article in Pharmacogenomics and personalized medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Primary cerebral melanoma of the frontal lobe: a case report and review of the literature.International journal of surgery case reports · 2026Article
- BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population.Plastic and reconstructive surgery. Global open · 2022Article
- Carotenoids from Marine Microalgae as Antimelanoma Agents.Marine drugs · 2022Review
- Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis.Cell death & disease · 2020Article
- Cold Atmospheric Plasma and Silymarin Nanoemulsion Activate Autophagy in Human Melanoma Cells.International journal of molecular sciences · 2020Article
- Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data.Scientific reports · 2019Article
- miR-204-5p and miR-3065-5p exert antitumor effects on melanoma cells.Oncology letters · 2018Article
- Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors.BMJ case reports · 2018Article
- Article
- Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Hormones & cancer · 2017Article
- Article
- Review
- BRAF gene: From human cancers to developmental syndromes.Saudi journal of biological sciences · 2015Review
- Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.PloS one · 2015Article
- The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation.Molecular cancer research : MCR · 2014Article
- Emerging targeted therapies for melanoma treatment (review).International journal of oncology · 2014Review
- Sirtuin deacetylases: a new target for melanoma management.Cell cycle (Georgetown, Tex.) · 2014Article
- Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.Journal of oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.